Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/4/2025

Management of Recurrent Paroxysmal Atrial Fibrillation

Introduction to Treatment

  • The American College of Cardiology recommends that the patient should start immediate long-term oral anticoagulant therapy and consider a rhythm control strategy with continuous prophylactic antiarrhythmic therapy, given the increased frequency of episodes 1, 2.

Oral Anticoagulation - Absolute Priority

  • The American College of Cardiology recommends starting oral anticoagulation immediately, regardless of the current rhythm, as the thromboembolic risk is determined by underlying risk factors, not the current rhythm 1, 2.
  • Calculate the CHA₂DS₂-VASc score: at 70 years, the patient already has at least 1 point (age 65-74 years), so anticoagulation is indicated 3.
  • Direct Oral Anticoagulants (DOACs) such as apixaban, rivaroxaban, edoxaban, and dabigatran are preferred over warfarin due to the lower risk of bleeding 3.
  • Anticoagulation should continue indefinitely, even if episodes decrease or cease, unless a clearly identifiable reversible trigger is present 1, 2.

Rhythm Control Strategy

Continuous Antiarrhythmic Prophylactic Therapy

  • With weekly episodes, the "pill-in-the-pocket" approach (propafenone as needed) is no longer appropriate - the patient requires continuous antiarrhythmic prophylactic therapy 1, 2, 3.

Selection of Antiarrhythmic Drug

  • For patients without structural heart disease:
  • If structural heart disease, heart failure, or left ventricular ejection fraction (LVEF) <40% is present:

Important Considerations for Continuous Therapy

  • Continuous prophylactic therapy significantly reduces the frequency and duration of episodes, even if it does not completely eliminate recurrences 4.
  • Associate a beta-blocker or non-dihydropyridine calcium antagonist to control AV conduction and prevent atrial flutter with 1:1 conduction 4.

Concomitant Heart Rate Control

  • Continue heart rate control with beta-blockers as first-line therapy 3.
  • Diltiazem or verapamil are alternatives if LVEF >40% 3.
  • Avoid digoxin as monotherapy because it is ineffective during exercise 3.

Necessary Cardiological Evaluation

  • The patient should be evaluated by a cardiologist for:

Critical Pitfalls to Avoid

  • Do not stop anticoagulation after cardioversion or prolonged periods in sinus rhythm - 70% of strokes occur in patients who have suspended anticoagulation or have subtherapeutic INR 8.
  • Never use amiodarone as initial therapy in patients without structural heart disease due to the risk of pulmonary, thyroid, hepatic, and ocular toxicity 4, 3.
  • Do not combine anticoagulants with antiplatelets unless there is a specific acute vascular indication 3.
  • Avoid antiarrhythmic drugs in patients with advanced conduction disorders without pacing 3.

Treatment Monitoring

  • Re-evaluate ECG after every dose modification to assess PR, QRS, and QT intervals 6.
  • Monitor heart rate weekly in the first few weeks 6.
  • Maintain potassium ≥4.0 mEq/L to reduce proarrhythmic risk 9.
  • Reduce digoxin and warfarin doses if amiodarone is started 6.

REFERENCES

3

Paroxysmal Atrial Fibrillation Management [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

7

Management of Bradycardia and Presyncope in Post-Ablation Patients [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025